Race Oncology (ASX:RAC) has announced a collaboration with the University of North Carolina, led by distinguished cardiologist-scientist and cardio-oncology key opinion leader, Dr Brian Jensen.
The precision oncology company says the partnership is to uncover the molecular mechanisms of how its drug, Zantrene can protect the heart from chemotherapy.
Race Oncology says the Phase 2/3 cancer drug can protect the heart from chemotherapy-induced damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve the ability to target breast cancer.
Shares of Race Oncology were up 3.26% this afternoon.